WO2009139891A3 - Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof - Google Patents
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof Download PDFInfo
- Publication number
- WO2009139891A3 WO2009139891A3 PCT/US2009/003016 US2009003016W WO2009139891A3 WO 2009139891 A3 WO2009139891 A3 WO 2009139891A3 US 2009003016 W US2009003016 W US 2009003016W WO 2009139891 A3 WO2009139891 A3 WO 2009139891A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alk1
- bmp9
- bmp10
- antagonists
- ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09746978A EP2291401A2 (en) | 2008-05-15 | 2009-05-15 | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
CA2724525A CA2724525A1 (en) | 2008-05-15 | 2009-05-15 | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5364408P | 2008-05-15 | 2008-05-15 | |
US61/053,644 | 2008-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009139891A2 WO2009139891A2 (en) | 2009-11-19 |
WO2009139891A3 true WO2009139891A3 (en) | 2010-02-18 |
Family
ID=40886532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/003016 WO2009139891A2 (en) | 2008-05-15 | 2009-05-15 | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2291401A2 (en) |
CA (1) | CA2724525A1 (en) |
WO (1) | WO2009139891A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
EP2087001B1 (en) | 2006-11-02 | 2016-10-26 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
TW201609138A (en) * | 2008-05-02 | 2016-03-16 | 艾西利羅製藥公司 | Methods and compositions for modulating angiogenesis and pericyte composition |
US20160228509A9 (en) * | 2009-05-08 | 2016-08-11 | Novartis Ag | Diagnostic BioMarkers for Fibrotic Disorders |
US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
PE20180041A1 (en) | 2015-06-05 | 2018-01-09 | Novartis Ag | ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN (BMP9) AND METHODS FROM THESE |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113590A2 (en) * | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
US20070065444A1 (en) * | 2005-09-07 | 2007-03-22 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
WO2008057461A2 (en) * | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897581B2 (en) * | 2005-02-24 | 2011-03-01 | Massachusetts Eye & Ear Infirmary | Methods and compounds for promoting vessel regression |
CA2703099A1 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Activin receptor-like kinase-i compositions and methods of use |
TW201609138A (en) * | 2008-05-02 | 2016-03-16 | 艾西利羅製藥公司 | Methods and compositions for modulating angiogenesis and pericyte composition |
-
2009
- 2009-05-15 EP EP09746978A patent/EP2291401A2/en not_active Withdrawn
- 2009-05-15 CA CA2724525A patent/CA2724525A1/en not_active Abandoned
- 2009-05-15 WO PCT/US2009/003016 patent/WO2009139891A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113590A2 (en) * | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
US20070065444A1 (en) * | 2005-09-07 | 2007-03-22 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
WO2008057461A2 (en) * | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
Non-Patent Citations (4)
Title |
---|
DAVID LAURENT ET AL: "Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 109, no. 5, 1 March 2007 (2007-03-01), pages 1953 - 1961, XP002490787, ISSN: 0006-4971, [retrieved on 20061026] * |
SCHARPFENECKER MARION ET AL: "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 120, no. 6, 1 March 2007 (2007-03-01), pages 964 - 972, XP002490785, ISSN: 0021-9533 * |
See also references of EP2291401A2 * |
UNGEFROREN HENDRIK ET AL: "Antitumor activity of ALK1 in pancreatic carcinoma cells", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 120, no. 8, 1 April 2007 (2007-04-01), pages 1641 - 1651, XP002490786, ISSN: 0020-7136 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009139891A2 (en) | 2009-11-19 |
EP2291401A2 (en) | 2011-03-09 |
CA2724525A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008057461A3 (en) | Alk1 receptor and ligand antagonists and uses thereof | |
WO2009134428A3 (en) | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage | |
WO2009139891A3 (en) | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof | |
WO2012003418A3 (en) | Functionally selective ligands of dopamine d2 receptors | |
WO2010030813A3 (en) | Methods for inhibiting ocular angiogenesis | |
MX2010005031A (en) | Axl antibodies. | |
WO2007024921A3 (en) | Combination therapies for inhibiting integrin-extracellular matrix interactions | |
MX355042B (en) | Methods for increasing thermogenic adipocytes. | |
PH12015501515A1 (en) | Anti-cmet antibody | |
PL2547679T3 (en) | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
WO2008155558A3 (en) | Microspheres | |
WO2009142732A3 (en) | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands | |
WO2009115572A3 (en) | Novel heterocyclic compounds and uses therof | |
MX2011011825A (en) | Humanized axl antibodies. | |
PL2094690T3 (en) | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | |
WO2014096440A3 (en) | Albumin composition for preventing and/or reducing formation of peptide fibrils | |
PL2013236T3 (en) | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk | |
WO2013169574A3 (en) | Aliphatic spirolactam cgrp receptor antagonists | |
UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
MX2014009277A (en) | Alk1 antagonists and their uses in treating renal cell carcinoma. | |
WO2009089234A3 (en) | Substituted dibenzhydrylpiperazines | |
WO2011106248A3 (en) | Trimethoxyphenyl inhibitors of tyrosine kinase | |
WO2008059339A3 (en) | Isoquinoline derivatives as vanilloid receptor modulators | |
WO2007005780A3 (en) | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | |
MX2010007669A (en) | Methods for inhibiting angiogenesis using egfl8 antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09746978 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 1011870 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20090515 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2724525 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009746978 Country of ref document: EP |